Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.97 USD
−53.47 M USD
0.00 USD
22.40 M
About Immuneering Corporation
Sector
CEO
Benjamin J. Zeskind
Headquarters
Cambridge
Website
Founded
2008
FIGI
BBG009QXJQS1
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of IMRX is 2.00 USD — it has increased by 8.70% in the past 24 hours. Watch Immuneering Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Immuneering Corporation stocks are traded under the ticker IMRX.
IMRX stock has risen by 8.11% compared to the previous week, the month change is a −1.96% fall, over the last year Immuneering Corporation has showed a −70.72% decrease.
We've gathered analysts' opinions on Immuneering Corporation future price: according to them, IMRX price has a max estimate of 25.00 USD and a min estimate of 1.50 USD. Watch IMRX chart and read a more detailed Immuneering Corporation stock forecast: see what analysts think of Immuneering Corporation and suggest that you do with its stocks.
IMRX reached its all-time high on Aug 6, 2021 with the price of 33.99 USD, and its all-time low was 1.00 USD and was reached on Aug 16, 2024. View more price dynamics on IMRX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
IMRX stock is 16.20% volatile and has beta coefficient of 3.01. Track Immuneering Corporation stock price on the chart and check out the list of the most volatile stocks — is Immuneering Corporation there?
Today Immuneering Corporation has the market capitalization of 62.10 M, it has decreased by −19.16% over the last week.
Yes, you can track Immuneering Corporation financials in yearly and quarterly reports right on TradingView.
Immuneering Corporation is going to release the next earnings report on Mar 5, 2025. Keep track of upcoming events with our Earnings Calendar.
IMRX earnings for the last quarter are −0.49 USD per share, whereas the estimation was −0.55 USD resulting in a 11.21% surprise. The estimated earnings for the next quarter are −0.46 USD per share. See more details about Immuneering Corporation earnings.
Immuneering Corporation revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
IMRX net income for the last quarter is −14.60 M USD, while the quarter before that showed −14.08 M USD of net income which accounts for −3.68% change. Track more Immuneering Corporation financial stats to get the full picture.
No, IMRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 68.00 employees. See our rating of the largest employees — is Immuneering Corporation on this list?
Like other stocks, IMRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Immuneering Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Immuneering Corporation technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Immuneering Corporation stock shows the sell signal. See more of Immuneering Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.